Publications & Resources

+ Expand all

PATHOPHYSIOLOGY OF ADPKD

Autosomal Dominant Polycystic Kidney Disease
https://www.nejm.org/doi/full/10.1056/NEJMcp0804458
Grantham JJ
N Engl J Med. 359; 14 - October 2, 2008


Cellular signaling in PKD: foreword
https://doi.org/10.1016/j.cellsig.2020.109625
Torres VE, and Ong ACM
Cellular Signaling  Volume 71, July 2020, 109625


Volume Progression in Polycystic Kidney Disease
https://www.nejm.org/doi/full/10.1056/nejmoa054341
Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, and Miller JP, for the CRISP Investigators
N Engl J Med. 354; 20 - May 18, 2006


Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
https://www.nejm.org/doi/full/10.1056/nejmoa1402685
Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, and Chapman AB, for the HALT-PKD Trial Investigators
N Engl J Med. 371; 24 - December 11, 2014


LIXIVAPTAN

Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model
https://pubmed.ncbi.nlm.nih.gov/31117065/
Wang X, Constans MM, Chebib FT, Torres VE, and Pellegrini L
Am J Nephrol. 49(6):487-493 – May 2019


Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981680/
Di Mise A, Venneri M, Ranieri M, Centrone M, Pellegrini L, Tamma G, and Valenti G
Int J Mol Sci. 26;21(1) – December 2019


Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
https://drive.google.com/file/d/1jMZL3aAUF9usW9RK9S6UrJdEQvBTCrXJ/view?usp=sharing
Bowman BT, Rosner MH.
Core Evid. 2013;8:47-56


VASOPRESSIN V2 RECEPTOR ANTAGONISM IN ADPKD

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist
https://doi.org/10.1038/nm935
Gattone VH 2nd, Wang X, Harris PC, and Torres VE
Nat Med. 9, 1323–1326 (2003).


Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
https://www.nejm.org/doi/full/10.1056/nejmoa1205511
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, and Czerwiec FS, for the TEMPO 3:4 Trial Investigators
N Engl J Med. 367; 25 - December 20, 2012


Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
https://www.nejm.org/doi/full/10.1056/NEJMoa1710030
Torres VE, Chapman AB, Devuyst O, Gransevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais, JD, Czerwiec FS, and Sergeyeva O, for the REPRISE Trial Investigators*
N Engl J Med. 377:1930-1942 - November 16, 2017


LIVER SAFETY

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
https://pubmed.ncbi.nlm.nih.gov/26188764/
Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, and Zimmer CA
Drug Saf. 38:1103–1113 – July 2015


Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933473/
Endo M, Katayama K, Matsuo H, Horiike S, Nomura S, Hayashi A, Ishikawa E, Harada T, Sugimoto R, Tanemura A, Sugimoto K, Isaji S and Ito M
Kidney Int Reports. 4:11, 1653–1657 – September 2019


Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease Using Quantitative Systems Toxicology Modeling
https://pubmed.ncbi.nlm.nih.gov/31909447/
Woodhead JL, Pellegrini L, Shoda LKM, and Howell BA
Pharm Res. 37:24 – January 2020